Literature DB >> 24615090

Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.

X J Zhang1, P Liu2, F Zhu2.   

Abstract

We aimed to investigate the association between genetic variants of the DNA repair genes XPG, CSB, XPC, CCNH, and MMS19L in the nucleotide excision repair (NER) pathway and risk of prostate cancer in a population in China. This study included 229 patients with newly diagnosed and histopathologically confirmed primary prostate cancer and 238 healthy controls. Genotyping of XPG, CSB, XPC, CCNH, and MMS19L were performed on a 384-well plate on the MassARRAY platform. Associations between the polymorphisms of the six genes and risk of prostate cancer were analyzed using conditional logistical regression. We found that the variant genotype TT of the XPG rs2296147 polymorphism was moderately significantly associated with a higher risk of prostate cancer compared to the wild-type genotype CC [odds ratio (OR)=1.79, 95% confidence interval (CI)=1.01-3.25], and individuals carrying the GG genotype of the CSB rs2228526 polymorphism were associated with an increased risk of prostate cancer (OR=1.95, 95%CI=1.02-3.74). The combination genotype of the XPG T allele and the CSB G allele was associated with a moderately higher risk of prostate cancer risk (OR=1.84, 95%CI=1.06-3.20). In conclusion, we found that polymorphisms in XPG rs2296147 and CSB rs2228526 were significantly associated with prostate cancer susceptibility in the Chinese population analyzed. Our results support the hypothesis that naturally occurring genetic variation of DNA repair genes increases susceptibility to prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24615090     DOI: 10.4238/2014.January.24.20

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  8 in total

1.  Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.

Authors:  Semanti Mukherjee; Chaitanya Bandlamudi; Matthew D Hellmann; Yelena Kemel; Esther Drill; Hira Rizvi; Kaitlyn Tkachuk; Aliya Khurram; Michael F Walsh; Marjorie G Zauderer; Diana Mandelker; Sabine Topka; Ahmet Zehir; Preethi Srinivasan; Myvizhi Esai Selvan; Maria I Carlo; Karen A Cadoo; Alicia Latham; Jada G Hamilton; Ying L Liu; Steven M Lipkin; Sami Belhadj; Gareth L Bond; Zeynep H Gümüş; Robert J Klein; Marc Ladanyi; David B Solit; Mark E Robson; David R Jones; Mark G Kris; Joseph Vijai; Zsofia K Stadler; Christopher I Amos; Barry S Taylor; Michael F Berger; Charles M Rudin; Kenneth Offit
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

2.  Lack of association between XPC Lys939Gln polymorphism and prostate cancer risk: an updated meta-analysis based on 3039 cases and 3253 controls.

Authors:  Haoran Wu; Zhong Lv; Xugang Wang; Liang Zhang; Naixin Mo
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Genetic Association of ERCC6 rs2228526 Polymorphism with the Risk of Cancer: Evidence from a Meta-Analysis.

Authors:  Xiaochun Lin; Yongfu Wu; Qingde Li; Hongying Yu; Xugui Li; Xiaohua Li; Jinkun Zheng
Journal:  Biomed Res Int       Date:  2022-04-15       Impact factor: 3.246

4.  Diagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Lu Yang; Ming Xu; Chuan-Bao Cui; Peng-Hai Wei; Shu-Zhi Wu; Zuo-Jie Cen; Xing-Xing Meng; Qiong-Guang Huang; Zhi-Chun Xie
Journal:  Cancer Manag Res       Date:  2018-11-05       Impact factor: 3.989

5.  Polymorphisms in ERCC2 and ERCC5 and Risk of Prostate Cancer: A Meta-Analysis and Systematic Review.

Authors:  Yi Liu; Yonghui Hu; Meng Zhang; Runze Jiang; Chaozhao Liang
Journal:  J Cancer       Date:  2018-07-16       Impact factor: 4.207

6.  XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.

Authors:  Fang Wang; Shao-Dan Zhang; Hong-Mei Xu; Jin-Hong Zhu; Rui-Xi Hua; Wen-Qiong Xue; Xi-Zhao Li; Tong-Min Wang; Jing He; Wei-Hua Jia
Journal:  Oncotarget       Date:  2016-03-08

7.  XPC exon15 Lys939Gln variant increase susceptibility to prostate adenocarcinoma: Evidence based on 4306 patients and 4779 controls.

Authors:  Feng Qin; Sheng-Lin Gao; Kai Xu; Quan-Xin Su; Ze Zhang; Li Shi; Li-Jie Zhu; Li-Feng Zhang; Li Zuo
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

8.  Effects of Xeroderma pigmentosum group C polymorphism on the likelihood of prostate cancer.

Authors:  Yidan Yan; Jianmin Xu; Bin Xu; Qiaxian Wen; Jing Zhou; Lifeng Zhang; Li Zuo; Guoqiang Lv; Yunfeng Shi
Journal:  J Clin Lab Anal       Date:  2020-06-02       Impact factor: 2.352

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.